Status:
NO_LONGER_AVAILABLE
Sotrovimab Expanded Access Treatment Protocol (COVID-19)
Lead Sponsor:
Vir Biotechnology, Inc.
Conditions:
Covid19
Eligibility:
All Genders
12+ years
Brief Summary
An expanded access program for sotrovimab administered intravenously to participants with COVID-19 illness who meet current authorized/approved criteria for use of sotrovimab.
Eligibility Criteria
Inclusion
- In the opinion of the investigator, meets the current Emergency Use Authorization (EUA) eligibility criteria for sotrovimab
- OR
- patients currently hospitalized for a non-COVID-19 illness who acquire COVID-19 (nosocomial infection) and otherwise meets all the current EUA eligibility criteria
Exclusion
- Hospitalized due to COVID-19 (excludes nosocomial infection)
- Require oxygen therapy due to COVID-19, OR who require an increase in baseline oxygen flow rate due to COVID-19
Key Trial Info
Start Date :
Trial Type :
EXPANDED_ACCESS
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT05235347
Last Update
November 10 2022
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Site
Palo Alto, California, United States, 94304
2
Site
Boston, Massachusetts, United States, 02114
3
Site
St Louis, Missouri, United States, 63110
4
Site
Seattle, Washington, United States, 98109